Create
Log in
Enquire now
US Patent 11884729 Anti-L1CAM antibodies and uses thereof
Overview
Structured Data
Issues
Contributors
Access by API
Access by API
Is a
Patent
0
Date Filed
June 27, 2019
0
Date of Patent
January 30, 2024
0
Patent Application Number
17250286
0
Patent Citations
US Patent 6989452 Disulfide prodrugs and linkers and stabilizers useful therefor
0
US Patent 7767429 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
0
US Patent 7951917 Method for making multispecific antibodies having heteromultimeric and common components
0
US Patent 8138313 Treatment of tumors using specific anti-L1 antibody
0
US Patent 8227577 Bivalent, bispecific antibodies
0
US Patent 8586713 Readily isolated bispecific antibodies with native immunoglobulin format
0
US Patent 9260521 Treatment of tumors using specific anti-L1 antibody
0
US Patent 9777060 Antibody binding specifically to human and mouse L1CAM protein, and use therefor
0
US Patent 10400037 Binding molecules, especially antibodies, binding to L1CAM (CD171)
0
US Patent 10865242 Method and compositions for cellular immunotherapy
0
•••
Patent Inventor Names
Hyo Jeong Hong
0
Heesu Chae
0
Jisu Hong
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
11884729
0
Patent Primary Examiner
Julie Wu
0
CPC Code
C12N 5/0636
0
C07K 16/2803
0
C07K 2317/31
0
C07K 2317/56
0
C07K 2317/565
0
C07K 2317/92
0
C07K 2317/55
0
C07K 2317/94
0
C07K 14/7051
0
C07K 2317/622
0
•••
Find more entities like US Patent 11884729 Anti-L1CAM antibodies and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE